With the recent surge in treatment options for inflammatory bowel disease (IBD), which is represented by ulcerative colitis and Crohn's disease, developing an appropriate treatment strategy for IBD is emerging as a rising topic in clinical practice.

This is due to the recent health insurance reimbursement extensions granted for treatments by multinational pharmaceutical companies, which have lowered the burden on site.

#Amid intensifying sales and marketing competition within the industry, the medical community is expected to revise its guidelines on selecting appropriate treatments.

Until now, tumor necrosis factor (TNF) blockers Humira (adalimumab) and Remicade (inflixim